Covid vaccine designed to target two variants approved for use in UK JCVI will decide whether to use Moderna-manufactured jab in planned autumn booster campaign The Guardian - UK · Aug 15, 2022
Once-a-year Covid jab approved for use in adults in UK The new Moderna vaccine could put an end to three or four injections a year - and fights Omicron Wales Online · Aug 15, 2022
‘Next generation’ Moderna coronavirus booster jab approved for use in UK adults The jab is the first to target two strains of Covid-19. The Independent UK · Aug 15, 2022
Southern Hemisphere to Get First mRNA Vaccine Facility Covid-19 vaccine maker Moderna announced Monday that it will open an mRNA vaccine manufacturing facility in the Australian city of Melbourne, a first for the southern hemisphere. The project will be based at one of Australia's largest universities, Monash, and will produce 100 million vaccine doses a year for Covid-19,… Asharq Al-Awsat · Aug 15, 2022
Moderna Whale Trades Spotted A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 14 strange trades. Benzinga · Aug 8, 2022
Looking At Moderna's Recent Whale Trades Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Aug 5, 2022
Nasdaq Surges Over 300 Points; Moderna Earnings Beat Expectations U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Wednesday. Benzinga · Aug 3, 2022
COVID-19 vaccine sales push Moderna past expectations in Q2 Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts The Independent UK · Aug 3, 2022
Lisa Jarvis: At last, a simple strategy for COVID booster shots The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots. Tribune News Service · Aug 2, 2022
Looking At Moderna's Recent Whale Trades Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Jul 29, 2022
US buying $1.7 billion of Moderna’s omicron-specific booster Moderna Inc. said it secured a $1.74 billion contract to supply the U.S. government with its new omicron-specific vaccine. Tribune News Service · Jul 29, 2022
This Is What Whales Are Betting On Moderna Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Jul 27, 2022
Should you wait for the omicron booster? Why experts say you should 'get it now!' If you're like most Americans, you've gotten your primary doses of a COVID-19 vaccine, but you haven't gotten the recommended booster shots. So if it's been several months since your last primary dose, you're probably due for a booster. Los Angeles Times · Jul 27, 2022
Boost now or wait? Many wonder how best to ride out COVID's next wave Gwyneth Paige didn’t want to get vaccinated against COVID-19 at first. With her health issues — hypertension, fibromyalgia, asthma — she wanted to see how other people fared after the shots. Then her mother got colon cancer. Tribune News Service · Jul 25, 2022
Benzinga · Jul 22, 2022 Recap Of Friday's Biotech Catalysts - End Of The Day Summary Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…
Benzinga · Jul 20, 2022 Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei
Chicago Sun-Times · Jul 20, 2022 Get fourth COVID booster now, or wait? CDC says get the shot now, but many hesitate About 70% of Americans 50 and older who got a first booster shot — and nearly as many of those 65 and older — haven’t gotten their second booster dose, the CDC says.
ABC News · Jul 20, 2022 COVID-19 vaccine Moderna is provisionally approved for kids under 5. This is what we know Australian children aged six months to five years could soon be rolling up their sleeves for a COVID-19 jab. Here's what parents need to know.
Tribune News Service · Jul 19, 2022 Novavax COVID shot for adults gains CDC advisers’ backing Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.
Benzinga · Jul 19, 2022 Moderna Whale Trades Spotted A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 23 strange trades.
The Guardian - AU · Jul 19, 2022 Covid vaccine provisionally approved in Australia for children aged six months to six years Moderna’s paediatric dose will become available only after Australian Technical Advisory Group on Immunisation gives advice
Benzinga · Jul 18, 2022 Check Out What Whales Are Doing With MRNA Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
WEKU · Jul 18, 2022 A dire moment in the pandemic ... was the chance he'd been waiting for How Sotiris Missailidis, head of R&D in Brazil's vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.
The Independent UK · Jul 18, 2022 Covid vaccine protection ‘short lived,’ booster doses essential, study confirms ‘Continual updating of our vaccinations and booster shots is critical,’ scientists say
ABC News · Jul 17, 2022 Australia has ordered millions more COVID vaccines than it needs. What are the options to deal with them? Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?